Media headlines about Merus (NASDAQ:MRUS) have been trending somewhat positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Merus earned a news impact score of 0.05 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 43.6568126847622 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

NASDAQ:MRUS opened at $18.10 on Friday. The firm has a market cap of $350.60, a price-to-earnings ratio of -4.22 and a beta of 0.08. Merus has a 1 year low of $13.23 and a 1 year high of $23.75.

Several research firms recently commented on MRUS. Royal Bank of Canada downgraded Merus from an “outperform” rating to a “sector perform” rating and set a $28.00 price objective on the stock. in a research note on Tuesday, January 2nd. BidaskClub upgraded Merus from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 30th. Wedbush restated an “outperform” rating and set a $32.00 target price on shares of Merus in a research report on Friday, January 12th. Finally, ValuEngine upgraded Merus from a “strong sell” rating to a “sell” rating in a research report on Monday, April 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. Merus currently has a consensus rating of “Hold” and a consensus target price of $30.00.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers.

Insider Buying and Selling by Quarter for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with's FREE daily email newsletter.